#TogetherSeparately: live virtual meetup to summarize data presented on February’s IASLC Targeted Therapies Meeting. March 13 at 3PM…
rdsupportMarch 11, 2024
By: Anthony Sireci, M.D., senior vice president, clinical biomarkers and diagnostics development, Loxo@Lilly Over the…
rdsupportJanuary 7, 2024
2023 Happy Lungs Project RET research update On Friday December 8th, the Happy Lungs Project…
rdsupportDecember 18, 2023
New published study with exciting preclinical results about the second generation RET inhibitor vepafestinib (TAS0953/HM06). Vepafestinib showed selectivity…
rdsupportOctober 10, 2023
New clinical trial testing amivantamab for patients who progressed on RET therapies: A Phase 1…
rdsupportOctober 8, 2023
By: Anthony Sireci, M.D., senior vice president, clinical biomarkers and diagnostics development, Loxo@Lilly Increasingly, cancer…
rdsupportJuly 27, 2023
Last week was the 2023 American Society of Clinical Oncology (ASCO) conference in Chicago. The…
rdsupportJune 19, 2023
Data of the Phase 1 Study of KL590586 (EP0031/A400), presented at ASCO, reported preliminary efficacy…
rdsupportJune 19, 2023
The DAVA’s 2nd Hawaii Global Summit on Thoracic Malignancies is a five-day meeting comprising seven…
rdsupportJune 19, 2023